Bioequivalence of exemestane in post-menopausal females

Abstract

The bioavailability of two exemestane tablet formulations was compared in 74 healthy post-menopausal females, aged 46 to 74 years, during a laboratory-blind, randomized, two-treatment, two-period, cross-over study under fed conditions. In each treatment phase subjects received a single dose (one tablet) of 25 mg exemestane (CAS 107868-30-4). Consecutive dosing was separated by a drug-free washout period of 21 d. Following each dosing, serial venous blood samples were collected over a period of 144 h for the determination of plasma exemestane concentrations by means of a validated LC-MS/MS method. The geometric mean C_max of exemestane for the reference and test products was 21.48 and 20.14 ng/mL, respectively. The corresponding mean AUC(0–∞) was 87.12 and 86.90 ng · h/mL. The median T_max for both products under investigation appeared at 1.70 and 1.97 h, respectively. The test product was well tolerated and shown to be bioequivalent to the reference product with respect to all primary pharmacokinetic variables investigated.

Key words

Aromatase inhibitor - CAS 107868-30-4 - Exemestane, bioavailability, bioequivalence, pharmacokinetics - Post-menopausal females

• Literature

• 1 Exemestane – Wikipedia. Available at http://en.wikipedia.org/wikiexemestane Accessed on 05 May 2009.
• 2 Product Monograph, Aromasin® (exemestane). Kirkland (Quebec): Pfizer Canada Inc.; 2003.
• 3 Buzdar AU, Robertson JFR, Eiermann W, Nabholtz JM.. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrazole, letrozole, and exemestane. Cancer. 2002; 95 (9) 2006-16
• 4 Aromasin™ 25 mg (Tablets) – Available at http://home.intekom.com/pharm/pharmaca/aromasin.html Accessed on 05 May 2009.
• 5 Brueggemeier RW. Aromatase, aromatase inhibitors, and breast cancer. Am J Ther. 2001; 8 (5) 333-44
• 6 Buzdar AU. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clin Cancer Res. 2003; 9 (Suppl) 468s-72s
• 7 Lønning PE, Geisler J, Bhatnager A. Development of aromatase inhibitors and their pharmacologic profile. Am J Clin Oncol. 2003; 26 (4) S3-S8
• 8 Mauras N, Lima J, Patel D, DiSalle E, Kwok A, Lippe B. Pharmacokinetics and dose finding of a potent aromatase inhibitor, Aromasin (exemestane), in young males. J Clin Endocrinol Metab. 2005; 88 (12) 5951-6
• 9 Lønning PE. Clinical pharmacokinetics of aromatase inhibitors and inactivators. Clin Pharmacokinet. 2003; 42 (7) 619-31
• 10 Valle M, DiSalle E, Jannuzzo MG, Pogessi I, Rochetti M, Spinelli R et al. A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation. Br J Clin Pharmacol. 2005; 59 (3) 355-64
• 11 ICH Guideline for Good Clinical Practice, ICH Harmonised Tripartite Guideline. CPMP/ICH/135/95; 2002.
• 12 Note for Guidance on investigation of bioavailability and bioequivalence, ICH Secretariat. CPMP/EWP/QWP/1401/978; 2001.
• 13 Registration of Medicines – Biostudies, version 2. Medicines Control Council of South Africa; Dec 2006.
• 14 Guidelines for Good Practice in the conduct of clinical trials in human participants in South Africa. Department of Health; 2000.
• 15 Diletti E, Hauschke D, Steinijans V. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharm, Ther Toxicol. 1992; 30: S51-S58
• 16 Standards for the practice of blood transfusion in South Africa, Chapter B. Blood Donors. 3rd edition. Elsevier Ltd.; 1999. p. 9.
• 17 Steinijans VW, Hauscke D. Update on the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1990; 28: 105-10
• 18 SAS/STAT Guide for Personal Computers, version 8.2. Cary (NC): SAS Institute Inc.
• 19 Guidance on the investigation of bioequivalence, ICH Secretariat. CPMP/EWP/QWP/1401/98 Rev. 1; 2009.